Vincere develops small molecule therapeutics to improve mitochondrial quality. Natural mechanisms of mitochondrial quality control decline with age, leading to the neurodegeneration seen in Parkinson's disease which affects 10 million patients worldwide.
Vincere is a recipient of a $1M grant from the Michael J Fox Foundation, a Phase I SBIR grant from the National Institutes of Health (NIH), and is a resident of the JLABS incubator at LabCentral in Cambridge, MA.
Biology is complex with a rapidly growing body of knowledge. Proprietary simulation and AI from NeuroInitiative enables our team to move faster and synthesize new discoveries into efficient therapeutic programs.